N
DNA icon

Nuveen’s Ginkgo Bioworks DNA Stock Holding History

Nuveen’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Buy
181,749
+2,111
+1% +$17.6K ﹤0.01% 2533
2025
Q4 		$1.49M Buy
179,638
+120,819
+205% +$1.3M ﹤0.01% 2416
2025
Q3 		$858K Buy
58,819
+8,241
+16% +$98.6K ﹤0.01% 2691
2025
Q2 		$569K Buy
+50,578
New +$392K ﹤0.01% 2839
2024
Q3 		– Sell
-670
Closed -$8.96K – 3339
2024
Q2 		$8.96K Sell
670
-107,207
-99% -$3.2M ﹤0.01% 3327
2024
Q1 		$5.01M Buy
107,877
+89
+0.1% +$4.61K ﹤0.01% 1995
2023
Q4 		$7.29M Buy
107,788
+6,648
+7% +$407K ﹤0.01% 1772
2023
Q3 		$7.32M Buy
101,140
+11,398
+13% +$911K ﹤0.01% 1667
2023
Q2 		$6.68M Buy
89,742
+16,933
+23% +$1M ﹤0.01% 1756
2023
Q1 		$3.87M Buy
72,809
+18,221
+33% +$1.15M ﹤0.01% 2032
2022
Q4 		$3.69M Sell
54,588
-16,297
-23% -$1.5M ﹤0.01% 2084
2022
Q3 		$8.85M Buy
70,885
+30,979
+78% +$3.69M ﹤0.01% 1555
2022
Q2 		$3.8M Buy
+39,906
New +$4.87M ﹤0.01% 2130

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's DNA Position: Q1 2026 in Review

Nuveen increased its Ginkgo Bioworks (DNA) stake by 1.2% in Q1 2026, buying an estimated $17.6K and bringing the position to 181,749 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2533.

Nuveen first reported a position in DNA in Q2 2022 and has held it in 13 quarters since. The position peaked at $8.85M in Q3 2022. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Nuveen held 181,749 shares of Ginkgo Bioworks worth $1.11M as of Q1 2026.
  • Nuveen bought 2,111 Ginkgo Bioworks shares in Q1 2026, an estimated $17.6K.
  • Ginkgo Bioworks made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2533 holding.
  • Nuveen first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 13 quarters since.
  • Nuveen's Ginkgo Bioworks position peaked at $8.85M in Q3 2022.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.